Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats

Neuropeptides
X F HuangKaterina Zavitsanou

Abstract

Using quantitative in situ hybridization, this study examined regional changes in rat brain mRNA levels encoding neuropeptide Y (NPY) following olanzapine, clozapine and haloperidol administration (1.2, 1.5 and 2.0 mg/kg, oral) for 36 days. The NPY mRNA expression levels and patterns were examined after the last drug administration at both time points enabling the measurement of immediate effect at 2h and the effects after 48 h of drug administration. It was found that all these drugs had an immediate effect on NPY mRNA expression, while virtually all these changes normalized 48 h after the drug treatments. A similarity in altered NPY mRNA expression patterns was seen between the olanzapine and clozapine groups; however, haloperidol was very different. Olanzapine and clozapine administration decreased NPY mRNA levels in the nucleus accumbens, striatum and anterior cingulate cortex (from -60% to -77%, p<0.05). Haloperidol decreased NPY mRNA expression in the amygdala and hippocampus (-69%, -64%, p<0.05). In the lateral septal nucleus, NPY mRNA levels significantly decreased in the olanzapine group (-66%, p<0.05), a trend toward a decrease was observed in the clozapine group, and no change was found in the haloperidol treated gro...Continue Reading

References

Jun 10, 1991·Neuroscience Letters·G Pelletier, J Simard
Jan 1, 1989·Annual Review of Psychology·R A Wise, P P Rompre
Jun 1, 1987·Neurochemical Pathology·M F BealJ B Martin
Mar 1, 1995·Pharmacology & Therapeutics·J G WettsteinJ L Junien
Jun 1, 1993·Physiology & Behavior·E YadinC E Strickland
Jan 15, 1996·Biological Psychiatry·S M GabrielK L Davis
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·G S Robertson, H C Fibiger
Sep 1, 1995·International Clinical Psychopharmacology·J Gerlach, L Peacock
Jul 28, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·E Obuchowicz, J Turchan
May 9, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·S IritaniK Ikeda
May 29, 2000·Trends in Cognitive Sciences·G BushM I Posner
Mar 29, 2001·Brain Research Bulletin·G van LuijtelaarJ G Veening
Nov 15, 2002·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Katerina ZavitsanouXu Feng Huang
Jun 26, 2003·Brain Research. Molecular Brain Research·Xu-Feng HuangLen H Storlien
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Katerina ZavitsanouXu Feng Huang
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Kenji IkedaKazuhiro Niizato
May 12, 2004·Behavioural Brain Research·Anibal A ArjonaRichard J Wurtman
Nov 6, 2004·Neuroscience and Biobehavioral Reviews·Ewa ObuchowiczZbigniew S Herman
Dec 4, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Yi-Qing MoWei-Xing Shi

❮ Previous
Next ❯

Citations

Oct 15, 2010·European Archives of Psychiatry and Clinical Neuroscience·J U SommerP J Gebicke-Haerter
Apr 28, 2007·The Australian and New Zealand Journal of Psychiatry·Daren M DraganicVaughan J Carr
May 30, 2009·Diabetes, Obesity & Metabolism·Richard I G Holt, Robert C Peveler
Dec 3, 2011·CNS Drugs·James L RoerigJames E Mitchell
Jan 2, 2013·Journal of Clinical Psychopharmacology·Arun K TiwariDaniel J Müller
May 15, 2013·Biological Psychiatry·Mira JakovcevskiSchahram Akbarian
Mar 21, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Chao DengXu-Feng Huang
Oct 16, 2015·Acta Neuropsychiatrica·Artur PalaszRyszard Wiaderkiewicz
Aug 1, 2015·Journal of Molecular Neuroscience : MN·Artur Pałasz, Ewa Rojczyk
Nov 9, 2010·Behavioural Brain Research·Katrina Weston-GreenChao Deng
Oct 7, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·J-P KlemettiläE Leinonen
Jan 1, 2016·Journal of Neurophysiology·Imran J AnwarAndrea Zsombok
Feb 3, 2007·Neurochemical Research·Katerina ZavitsanouXu Feng Huang
Oct 31, 2018·Frontiers in Neuroscience·Minmin HuXu-Feng Huang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amygdala and Midbrain Dopamine

The midbrain dopamine system is widely studied for its involvement in emotional and motivational behavior. Some of these neurons receive information from the amygdala and project throughout the cortex. When the circuit and transmission of dopamine is disrupted symptoms may present. Here is the latest research on the amygdala and midbrain dopamine.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Amygdala: Sensory Processes

Amygdalae, nuclei clusters located in the temporal lobe of the brain, play a role in memory, emotional responses, and decision-making. Here is the latest research on sensory processes in the amygdala.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.